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Long-term patternsObjectives: To identify patterns of long-term, radiation-induced swallowing dysfunction after definitive
radiotherapy with or without chemotherapy (RT or CHRT) and to determine which factors may explain
these patterns over time.
Material and methods: The study population consisted of 238 consecutive head and neck cancer patients
treated with RT or CHRT. The primary endpoint was Pgrade 2 swallowing dysfunction at 6, 12, 18 and
24 months after treatment. Cluster analysis was used to identify different patterns over time. The differ-
ences between the mean dose to the swallowing organs at risk for each pattern were determined by using
dose maps.
Results: The cluster analysis revealed five patterns of swallowing dysfunction: low persistent, intermedi-
ate persistent, severe persistent, transient and progressive. Patients with high dose to the upper pharyn-
geal, laryngeal and lower pharyngeal region had the highest risk of severe persistent swallowing
dysfunction. Transient problems mainly occurred after high dose to the laryngeal and lower pharyngeal
regions, combined with moderate dose to the upper pharyngeal region. The progressive pattern was
mainly seen after moderate dose to the upper pharyngeal region.
Conclusions: Various patterns of swallowing dysfunction after definitive RT or CHRT can be identified
over time. This could reflect different underlying biological processes.
 2015 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 117 (2015) 139–144
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Radiation-induced swallowing dysfunction is a clinically rele-
vant late side effect after definitive radiotherapy (RT) or chemora-
diation (CHRT) in patients with head and neck squamous cell
carcinoma (HNSCC) which has a substantial impact on health-
related quality of life (HRQoL) [1–3]. During and shortly after RT
or CHRT, almost all HNSCC patients suffer from a certain degree
of swallowing dysfunction. In most cases, acute swallowing dys-
function markedly improves during the first months after treat-
ment. However, 2 years after treatment, many patients still suffer
from grade 2 or higher swallowing dysfunction [4–9].
Recently, we reported on a multivariable Normal Tissue Com-
plication Probability (NTCP) model for grade 2–4 swallowing dys-
function at 6 months after definitive RT or CHRT (SWALM6). Inthat study, the mean dose to the superior pharyngeal constrictor
muscle (superior PCM) and the mean dose to the supraglottic lar-
ynx were the two most important prognostic factors for SWALM6
[10]. One of the limitations of that study was that the primary end-
point was taken at 6 months after completion of treatment, while
other investigators showed that swallowing dysfunction may
improve or deteriorate beyond 6 months. Consequently, patients
may show various patterns over time [5,6,8,9], which may reflect
various underlying radiobiological mechanisms. For instance,
swallowing dysfunction at 6 months that gradually decreases dur-
ing longer follow-up is more likely due to recovering mucositis and
laryngeal edema, while progressive swallowing dysfunction after a
longer period (e.g. requiring dilatation) is more likely to result from
progressive fibrosis. We decided to conduct a prospective cohort
study to determine which factors are related to these various pat-
terns. After our first swallowing dysfunction analysis at 6 months,
all patients remained included in a standard follow-up program,
140 Patterns long-term swallowing dysfunctionwhich included a subsequent prospective assessment of swallow-
ing dysfunction up to 24 months after completion of treatment.
The purpose of the present study was to identify patterns of
long-term, radiation-induced swallowing dysfunction after com-
pletion of definitive RT or CHRT and to determine which factors
could explain these patterns.
Methods and materials
Patients
The study population of this prospective cohort study consisted
of 238 consecutive patients, treated from 1997 at two medical cen-
ters in the Netherlands: the VU University Medical Center (VUMC),
Amsterdam or the University Medical Center Groningen (UMCG),
Groningen. For the purpose of this analysis, we only included the
238 patients with a minimal follow-up of 24 months and a maxi-
mum of 1 missing value on swallowing function. We decided to
limit the analysis up to 24 months as the number of patients
dropped beyond that interval due to end of follow-up or death.
All patients were treated with curatively intended conventional
three-dimensional conformal RT (3D-CRT) or intensity-modulated
RT (IMRT) for HNSCC, either alone or in combination with con-
comitant chemotherapy. All patients were subjected to a prospec-
tive standard follow-up program including assessment of toxicity
and HRQoL prior to, during and at regular intervals after treatment
[10–12].
Patients who previously underwent surgery, RT or CHRT, who
had prior malignancies, and/or distant metastases were excluded.
Patients with RTOG grade 2–4 swallowing dysfunction at baseline
were also excluded to ensure that the observed swallowing dys-
function was induced by radiation treatment and not by tumor
extension. The patient characteristics are listed in Table 1.Endpoints
The endpoint was defined as the grade of swallowing dysfunc-
tion according to the RTOG/EORTC Late Radiation MorbidityTable 1
Patient characteristics.
Characteristics All patients Low
pers
Number % Num
Sex Male 175 74 105
Female 63 26 20
Age, years 18–65 156 66 76
>65 82 34 49
Tumor classification T1–T2 161 68 98
T3–T4 77 32 27
Node classification N0 154 65 103
N+ 84 35 22
Primary Site Larynx 136 57 96
Oropharynx 71 30 20
Oral cavity 11 5 4
Hypopharynx 12 5 3
Nasopharynx 8 3 2
Treatment modalities Conventional RT 33 14 21
Accelerated RT 155 65 93
Chemoradiation 50 21 11
Radiation technique 3D-CRT 155 65 88
IMRT 83 35 37
Neck irradiation No or unilateral 66 28 48
Bilateral 172 72 77
Baseline swallowing dysfunction (RTOG) Grade 0 209 88 115
Grade 1 29 12 10
Abbreviations: RT = radiotherapy, 3D-CRT = three-dimensional conformal RT, IMRT = inteScoring Criteria as assessed at 6, 12, 18 and 24 months after com-
pletion of RT or CHRT.Treatment
Until the end of 2007, the majority of patients were treated with
3D-CRT. Since 2008 patients were mainly treated with IMRT.
Regions of interest, RT planning and optimization, and chemother-
apy schedules were described previously in more detail [10–12].
All organs at risk (OARs), including the salivary glands, and the
swallowing organs at risk (SWOARs), including the superior, mid-
dle and inferior PCM, the cricopharyngeal muscle, the esophagus
inlet muscle (EIM), the cervical esophagus (CE), the base of tongue
(BOT) and the supraglottic and glottic larynx, were delineated as
previously described [13,14].Statistics
In order to classify the patients into patterns of swallowing dys-
function over time, we used a two-step cluster analysis. Cluster
analysis creates groups of cases that are homogeneous within
themselves, but heterogeneous between each other, based on a
predefined set of variables [15–17]. The degree of swallowing dys-
function at baseline and at all subsequent time points (at 6, 12, 18
and 24 months) were considered for cluster modeling based on
their contribution to characterizing the patterns of long-term,
radiation-induced swallowing dysfunction.
The baseline characteristics for the various pattern groups were
then compared on an explorative basis, thus comparing patients
with no or minor swallowing dysfunction to the other patterns,
using T-Test or chi-squared test, whenever appropriate.
For all the SWOARs we produced DVHs for all individual
patients. The differences between the mean dose to the SWOARs
of each pattern were determined using dose maps. Dose maps
are tables with the mean dose for each SWOAR, for each patient
grouped per pattern. By using a color scale (from white (lowest






ber % Number % Number % Number % Number %
84 25 64 11 58 25 69 9 47
16 14 36 8 42 11 31 10 53
61 27 69 15 79 27 75 11 58
39 12 31 4 21 9 25 8 42
78 25 64 7 37 19 53 12 63
22 14 36 12 63 17 47 7 37
82 24 62 2 11 15 42 10 53
18 15 38 17 89 21 58 9 47
77 20 51 2 11 12 33 6 32
16 13 33 11 58 18 50 9 47
3 2 5 2 11 1 3 2 11
2 1 3 3 15 4 11 1 5
2 3 8 1 5 1 3 1 5
17 3 8 2 10 4 11 3 16
74 27 69 6 32 19 53 10 53
9 9 23 11 58 13 36 6 31
70 19 49 12 63 21 58 15 79
30 20 51 7 37 15 42 4 21
38 9 23 0 0 4 11 5 26
62 30 77 19 100 32 89 14 74
92 32 82 16 84 29 81 17 89
8 7 18 3 16 7 19 2 11
nsity-modulated RT
M.E.M.C. Christianen et al. / Radiotherapy and Oncology 117 (2015) 139–144 141between the patterns can be visualized. These dose maps represent
the calculated dose based on the initial treatment planning.
We used our previously published multivariable NTCP model
for grade 2–4 swallowing dysfunction as the reference model for
the current analysis. In that model, the mean dose to the superior
PCM and the mean dose to the supraglottic larynx were the two
most important prognostic factors [10]. In order to study changes
over time, we tested the predictive value of this NTCP model at
6, 12, 18 and 24 months after completion of treatment.
Results
Swallowing dysfunction at different time points
The prevalence of grade 2–4 swallowing dysfunction was 22% at
6 months after RT or CHRT (52 patients), 14% at 12 months (33
patients), 12% at 18 months (29 patients), and 14% at 24 months
(33 patients) (Table 2).Patterns of swallowing dysfunction
With the two-step cluster analysis, we identified five patterns
for long-term, radiation-induced swallowing dysfunction within
the studied population (Fig. 1):
(1) Low persistent pattern: including those with no or minor
swallowing dysfunction during follow-up (125 patients;
53%).
(2) Intermediate persistent pattern: indicating some swallow-
ing dysfunction (grade 1) at 6 months after RT or CHRT
which remained more or less unchanged during follow-up
(39 patients; 16%).
(3) Severe persistent pattern: defined as swallowing dysfunc-
tionPgrade 2 at 6 months after RT or CHRT which remained
up to two year follow-up (19 patients: 8%).Fig. 1. Patterns of swallowing dysfunction. Percentage of patients in the different
transient = 15% and low persistent = 53%.
Table 2











6 months 41 37 13 8 1
12 months 53 33 8 5 1
18 months 57 31 7 4 1
24 months 62 23 10 4 1(4) Transient pattern: including patients with swallowing
dysfunction Pgrade 2 at 6 months after RT or CHRT, that
recovered during follow-up (36 patients; 15%).
(5) Progressive pattern: patients with <grade 2 swallowing dys-
function at 6 months after RT or CHRT, which progressed
during follow-up to at least grade 2 (19 patients; 8%).
Patient characteristics according to pattern
Of the 238 patients, 74% were males and the mean age was
62 years (range 33–92). The patient characteristics for the various
patterns are listed in Table 1. The baseline characteristics were par-
ticularly different when patients in the severe persistent pattern
group were compared to those in the low persistent pattern group.
These patients had higher T-stages and N-stages, had more pri-
mary tumors originating from the oropharynx, oral cavity or
hypopharynx, were more often treated with CHRT, with bilateral
neck irradiation and with conventional RT instead of accelerated
RT.
Compared to patients in the low persistent pattern group,
patients in the progressive pattern group were more often female,
had higher N-stages, and their primary tumors more often origi-
nated from the oropharynx or oral cavity.
At six months after treatment patients in the transient pattern
group had Pgrade 2 swallowing dysfunction, compared to grade
1 in the intermediate persistent pattern group. Over the longer
term (12–24 months), no difference in swallowing dysfunction
was found between these two groups. However, between these
two groups no significant differences were found with regard to
baseline characteristics.
The progressive pattern group had the lowest percentage of
patients treated with IMRT (Table 1), and these patients were on
average somewhat older than patients in the other groups.DVH characteristics according to pattern
To visualize differences in dose distributions across the pat-
terns, dose maps for each pattern group were created, including
information on the average Dmean to the SWOARs and salivary
glands. These structures were grouped according to anatomical
location into four main regions, including the upper pharyngeal
region (superior PCM, BOT and middle PCM), the lower pharyngeal
region (inferior PCM, cricopharyngeal muscle, EIM and CE), the
laryngeal region (supraglottic and glottic larynx) and the salivary
glands (parotid and submandibular glands).patterns: severe persistent = 8%, progressive = 8%, intermediate persistent = 16%,
Fig. 2. Average Dmean for each pattern group for each organ at risk Color scale used: from white (lowest Dmean) to red (highest Dmean), grouped per anatomical location. The
intensity of the red color corresponds with the level of the mean dose in that specific structure. Abbreviations: PCM = pharyngeal constrictor muscle.
142 Patterns long-term swallowing dysfunctionFrom the dose maps, the most important observations were:
(1) Increasing dose levels were observed from the low persis-
tent pattern group to the intermediate persistent and severe
persistent pattern groups. Patients in the low persistent pat-
tern group generally received lower mean doses to almost all
structures, except to the cricopharyngeal muscle and the
glottic larynx. These findings corresponded with the results
presented in Table 1, showing that the low persistent pat-
tern group mainly consisted of patients with T1–T2, N0
laryngeal cancers.
(2) The dose maps of patients in the transient pattern group
were characterized by high average dose levels to the lower
pharyngeal structures and the larynx, combined with lower
dose levels to the upper pharyngeal structures and salivary
glands, as compared to the severe persistent pattern.
(3) Patients in the progressive pattern group were characterized
by the lowest dose levels to the lower pharyngeal and laryn-
geal structures and higher doses to the upper pharyngeal
structures and the salivary glands.
NTCP model for grade 2–4 swallowing dysfunction at 6 months after
definitive RT or CHRT
For this subset of 2 year survivors, we tested if the impact of the
two independent prognostic factors included in the previously
described NTCP model for SWALM6 changed over time. When look-
ing at the odds ratios of the mean dose to the superior PCM and the
mean dose to the supraglottic larynx at 6, 12, 18 and 24 months
after completion of RT or CHRT, a decreasing contribution of the
mean dose to the supraglottic larynx was noted over time, whereas
the mean dose to the superior PCM remained more or less stable
and was a significant prognostic factor over time (Fig. 2).Discussion
The purpose of this prospective cohort study was to identify
patterns of long-term, radiation-induced swallowing dysfunctionafter definitive RT or CHRT. The cluster analysis indeed revealed
five patterns of swallowing dysfunction over time. Swallowing
dysfunction can be persistent (low, intermediate or severe), tran-
sient or progressive; we hypothesize that this difference is due to
underlying radiobiological mechanisms.
The low persistent pattern group was characterized by rela-
tively high dose levels to the glottic larynx and lower dose levels
to the other anatomical structures. This pattern group mainly con-
sisted of patients with early glottic cancer without nodal metas-
tases, treated with small volume irradiation on the primary site
only, without elective nodal irradiation (Table 1). Our findings indi-
cate that the combination of these low-risk characteristics explain
the relatively low levels of long-term swallowing dysfunction.
The primary endpoint chosen in our study was defined as swal-
lowing dysfunction according to the RTOG/EORTC Late Radiation
Morbidity Scoring Criteria as assessed at 6, 12, 18 and 24 months
after completion of RT or CHRT. As a consequence, the patterns
found in this study only refer to late morbidity according to the
RTOG/EORTC. It should be noted that different methods to score
swallowing dysfunction using other morbidity scoring systems
(e.g. the Common Terminology Criteria for Adverse Events
(CTCAE)), or using objective methods such as videofluoroscopy
(VF) or Functional Endoscopic Evaluation of Swallowing (FEES),
will likely lead to different outcomes and hence might lead to dif-
ferent patterns of long-term swallowing dysfunction [5,7,10]. In
the current study, similar swallowing patterns were found for
patient-rated swallowing dysfunction.
Compared to patients in the severe persistent pattern group,
those in the transient pattern group received similar dose levels
to the lower pharyngeal and laryngeal regions, but substantially
lower dose levels to the upper pharyngeal region. Thus, higher dose
levels to the laryngeal and lower pharyngeal region combined with
moderate dose levels to the upper pharyngeal region are more
likely to result in transient swallowing dysfunction. In this regard,
the results of the current study are in line with the clinical obser-
vations of other studies showing laryngeal edema occurring imme-
diately after treatment gradually decreasing over time [2,4,18].
Moreover, a number of investigators found a clear relationship
Fig. 3. Effect size (Odds ratio) of the mean dose to the superior PCM and supraglottic larynx on swallowing dysfunction. The effect of the superior PCM remains more or less
similar over time, while the effect of the mean supraglottic larynx dose gradually decreases to almost zero at 24 months. Abbreviations: PCM = pharyngeal constrictor muscle.
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to the larynx remains below approximately 44 Gy, edema is
generally less profound and more likely to resolve [2,18–21].
Popovtzer et al. [22] found increased muscle thickness in the
pharyngeal constrictor muscles on MRI at 3 months after CHRT,
especially when the dose to the PCM was above 50 Gy, suggesting
that pharyngeal constrictor dysfunction at 3 months after CHRT is
mainly caused by inflammation and edema.
It is also interesting to compare the transient with the progres-
sive pattern group. With regard to the dose distributions, the dose
to the laryngeal and lower pharyngeal region was much lower in
the progressive pattern group. On average, only the dose level to
the superior PCM and the BOT was somewhat higher in the pro-
gressive pattern group. Based on the dose distributions parame-
ters, it therefore remains unclear which anatomical structure
should be considered responsible for the progressive pattern. It
should be noted that patients with the progressive pattern were
predominantly treated with 3D-CRT instead of IMRT, were some-
what older than the patients in other pattern groups and consisted
of relatively more females (Table 1), but it remains unclear
whether and to what extent these factors play a role in the patterns
of swallowing dysfunction.
When comparing the current study with our previous reported
studies [6,10] there is some bias in favor of the node negative
patients and patients treated with radiotherapy alone, as the death
rates in the first 2 years after treatment were somewhat higher in
the advanced cases treated with CHRT.
The pattern groups differed substantially with regard to the
dose levels to the salivary glands. A gradual increase in dose
to the salivary glands was noted from patients with the low,
intermediate and severe persistent pattern. In contrast, the
patients in the transient pattern group received much lower
doses to the salivary glands than those in the severe persistent
pattern group. So far, it remains unclear to what extent xerosto-
mia plays a role in late swallowing dysfunction after RT or CHRT.
Other investigators have shown that when the dose to the sali-
vary glands is reduced, while the dose levels to swallowingorgans at risk remains the same, the level of swallowing dys-
function also decreased [7,19,23–25]. This suggests that saliva
indeed plays a role in lubrication and subsequent swallowing
dysfunction. We showed that intermediate persistent cases
received higher doses to the salivary glands as well as to the
upper pharyngeal swallowing structures as compared to patients
with low persistent patterns, suggesting that intermediate per-
sistent swallowing dysfunction may be either due to salivary
dysfunction or direct radiation damage to the swallowing struc-
tures. Furthermore, it should be noted that in the first year after
RT or CHRT, salivary flow and patient rated xerostomia may
recover to some extent [24,26–28]. Based on these results, at
least part of the recovery from swallowing dysfunction as
observed in the transient group could possibly be explained by
concomitant recovery of salivary function over time.
Based on the results of the current study, it appears that severe
persistent and progressive swallowing dysfunction is mainly
related to the anatomical structures in the upper pharyngeal
region. These results are supported by the results shown in
Fig. 3. In the long-term results, the importance of the dose to the
supraglottic larynx appears to decline, while the effect of the dose
to the superior PCM remains more or less stable. Therefore, to pre-
vent long-term swallowing dysfunction, we suggest keeping the
dose to the superior PCM as low as possible.
New radiation technologies like swallowing sparing IMRT (SW-
IMRT) [5,29] might reduce the risk of persistent swallowing dys-
function. Feng et al. [5] found that in patients with oropharyngeal
cancer high locoregional tumor control rates can be obtained with
IMRT aiming to reduce swallowing dysfunction. It should be noted
that these investigators excluded the medial retropharyngeal
nodes from the target volume to facilitate sparing of PCM. The
SW-IMRT described by Van der Laan et al. [29] is currently being
validated in a subsequent cohort study at our institutions. In this
regard, swallowing sparing intensity modulated proton therapy
(SW-IMPT) [30] is even more promising, as the dose to multiple
OARs, including to multiple SWOARs and salivary glands, can be
reduced even further.
144 Patterns long-term swallowing dysfunctionIn conclusion, we identified five patterns of swallowing dys-
function after definitive RT or CHRT. We hypothesize that this dif-
ference is due to underlying radiobiological mechanisms of
radiation-induced damage and recovery: including (reversible)
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